Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICStandard

EYSUVIS

LOTEPREDNOL ETABONATE

Standard Dose
0.25%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview EYSUVIS is listed in Drugs@FDA under application 210933 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LOTEPREDNOL ETABONATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.25% Sponsor ALCON LABS INC Submission history Latest submission status date: 2020-10-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview EYSUVIS is listed in Drugs@FDA under application 210933 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LOTEPREDNOL ETABONATE Form and strength SUSPENSION/DROPS;OPHTHALMIC - 0.25% Sponsor ALCON LABS INC Submission history Latest submission status date: 2020-10-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.